


Product ID V9202 CAS No. 479543-46-9 Chemical Name

Synonym VX702

C <sub>19</sub> H <sub>12</sub> F <sub>4</sub> N <sub>4</sub> O <sub>2</sub>
404.32
≥ <b>98</b> %
DMSO 81 mg/mL (200.34 mM) Water Insoluble Ethanol Insoluble
-20°C
Ambient
VX-702 inhibits p38 MAPK, preventing p38 MAPK-depende



## **Product Information**



## Bulk quanitites available upon request

Product ID	Size
V9202	5 mg
V9202	25 mg
V9202	100 mg

escription VX-702 inhibits p38 MAPK, preventing p38 MAPK-dependent inflammatory cytokine release. VX-702 is in development to treat inflammation and cardiovascular diseases and currently shows mixed results in clinical trials as a potential treatment for rheumatoid arthritis. In vitro, VX-702 decreases platelet lesioning in storage without affecting platelet function.

**References** Skripchenko A, Awatefe H, Thompson-Montgomery D, et al. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. PMID: 23967093.

Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592.

Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94. PMID: 16378500.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.